On January 11, 2026, Stoke Therapeutics announced that it expects to have approximately $391.7 million available to fund operations into 2028, alongside updates on its Phase 3 clinical trial of zorevunersen. The enrollment of 150 patients is anticipated to be completed by Q2 2026, with data readout expected in mid-2027.